IMNM
Immunome Inc
NASDAQ · Biotechnology
$24.88
+0.88 (+3.67%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 17.01M | 603.96M | 550.96M | 661.77M |
| Net Income | -551,235,025 | -173,219,826 | -162,867,502 | -187,119,094 |
| EPS | — | — | — | — |
| Profit Margin | -3,240.4% | -28.7% | -29.6% | -28.3% |
| Rev Growth | — | +13.0% | +19.7% | +11.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 349.67M | 358.31M | 392.24M |
| Total Equity | — | 1.78B | 1.86B | 1.97B |
| D/E Ratio | — | 0.20 | 0.19 | 0.20 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -572,441,464 | -273,358,868 | -247,027,649 | -323,672,786 |
| Free Cash Flow | — | -130,399,233 | -192,377,550 | -194,010,121 |